Abstract
Background Theta burst stimulation (TBS) is an efficient form of repetitive transcranial magnetic stimulation, but tolerability may depend on target and stimulation pattern, limiting translation to accelerated protocols.
Objective To estimate tolerable intensities for intermittent TBS (iTBS) over F3, approximating left dorsolateral prefrontal cortex, and continuous TBS (cTBS) over Fp1, intended to engage more anterior ventral/frontopolar circuitry, in non-treatment-seeking adults with obesity or tobacco use disorder.
Methods In an open-label randomized crossover titration study, 64 adults completed two TBS visits 7 days apart. Each visit included 3 sessions of 600 pulses, beginning at 80% resting motor threshold (RMT) with protocol-permitted escalation or de-escalation. The primary endpoint was participant-level maximum final maintained intensity. Bayesian grouped-binomial logistic regression estimated the intensity tolerated by 70% of participants (ED70), and a prespecified rule selected the highest dose with at least 80% posterior probability of meeting 70% tolerability.
Results Observed tolerability at 80% RMT was 86.4% for iTBS and 51.6% for cTBS. Primary-model ED70 was 105.5% RMT (95% credible interval [CrI], 99.0%-113.9%) for iTBS and 69.2% RMT (95% CrI, 65.0%- 73.4%) for cTBS. The recommended intensity was 100% RMT for iTBS and 60% RMT for cTBS; no cTBS dose at or above 80% RMT met criterion. cTBS produced greater immediate symptom burden, whereas 24-hour symptoms were uncommon.
Conclusion iTBS over F3 supported a future-trial design window of 90%-100% RMT, whereas cTBS over Fp1 showed a tolerability ceiling below 80% RMT. Future cTBS protocols targeting ventral prefrontal circuitry may need to move dorsally to improve tolerability.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT06991062 (BRAIN) and NCT06639594 (RAPID)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants came from 2 prospective, non-treatment-seeking cohorts: the BRAIN study (n = 43), which enrolled adults with tobacco use disorder and the RAPID study (n = 21), which enrolled adults with obesity. Both studies were approved by the MD Anderson Cancer Center institutional review board (RAPID, 2024-0261, approved October 2, 2024, activated November 21, 2024; BRAIN, 2024-1316, approved January 30, 2025, activated February 19, 2025). All participants provided written informed consent. ClinicalTrials.gov identifiers were NCT06991062 (BRAIN) and NCT06639594 (RAPID).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was supported by the NIH grant R61DA061689 (to G.K. and F.V.), the MD Anderson Cancer Center Support Grant P30CA016672, an award from the Baylor College of Medicine Houston Nutrition and Obesity Research Center, and generous philanthropic contributions to the Cancer Neuroscience Program of The University of Texas MD Anderson Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies that supported this work.
Data Availability
Data are from registered clinical trials involving human participants. De-identified data and associated materials may be made available to qualified investigators upon reasonable request to the corresponding authors, subject to the scope of participant consent, institutional review and data-use agreements, privacy and confidentiality protections, and applicable NIH data-management and sharing requirements and approved study data-sharing plans.
Funder Information Declared
